Therefore, targeting PTEN or DNMT, via silencing the DNMT1 gene or using DNMT inhibitors to prevent PTEN hypermethylation and expression deficiency, and negatively regulate the AKT/ERK pathway, thereby inhibiting HSC activation and alleviating liver fibrosis. Here, AKT1 is linked to Hepatic fibrosis.